Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Patricia Pautier1, Elsa Kalbacher2, Thibault de la Motte Rouge3

  • 1Département de médecine oncologique, Gustave-Roussy, Villejuif, France; Service d'oncologie médicale, CHRU de Besançon, France.

Bulletin Du Cancer
|June 20, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immuno-molecular features associated with exceptional recurrence-free survivorship from Ovarian Cancer in the pre-PARP era.

NPJ genomic medicine·2026
Same author

Para-aortic lymphadenectomy after negative PET-CT in locally advanced cervical cancer: a continuous monocentric series of 320 cases.

Gynecologic oncology·2026
Same author

[French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of advanced cervical cancer].

Bulletin du cancer·2026
Same author

Surgical treatment of vaginal and vulvar melanoma: a 18-year retrospective study.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Surgical approach and maintenance therapy in advanced low-grade serous ovarian cancer: Insights from the French ESME database.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2025
Same author

Long-term quality of life in non-epithelial ovarian cancer survivors: TMRG-GINECO-Vivrovaire rare tumors case-control study.

BMC medicine·2025
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles

Early relapse in ovarian cancer is defined as disease recurrence within six months of platinum chemotherapy. Treatment involves non-platinum agents, with bevacizumab as an option for eligible patients.

Area of Science:

  • Oncology
  • Gynecologic Oncology

Background:

  • Early relapse of ovarian cancer presents a significant clinical challenge.
  • Defining early relapse is crucial for treatment stratification.

Purpose of the Study:

  • To define early relapse in ovarian cancer.
  • To outline appropriate treatment strategies for patients experiencing early relapse.

Main Methods:

  • Relapse occurring less than 6 months before the last platinum-based chemotherapy infusion.
  • Exclusion of cases with carcinological surgical indications.

Main Results:

  • Treatment recommendations include single-agent non-platinum chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel, gemcitabine, or topotecan).
  • Bevacizumab may be added if not previously administered, supported by high-level evidence (level 1, grade A).
Keywords:
Cancer de l’ovaireEarly relapseOvarian cancerRechute précoce

Related Experiment Videos

Conclusions:

  • Early relapse in ovarian cancer necessitates specific treatment approaches.
  • Non-platinum agents and potentially bevacizumab form the basis of management for this patient group.